Option Care Announces Fourth Quarter and Year-End 2003 Results

Date : 02/17/2004 @ 8:01AM
Source : PR Newswire
Click here for ADVFN's up to the minute news service. Access our extensive collection of financial news from around the world including US, Europe and Asia.
<< Back

 



Option Care Announces Fourth Quarter and Year-End 2003 Results

Option Care Announces Fourth Quarter and Year-End 2003 Results Q4 Revenue of $96 Million; Earnings Per Diluted Share of $0.19

BUFFALO GROVE, Ill., Feb. 17 /PRNewswire-FirstCall/ -- Option Care, Inc. today reported results for the fourth quarter and year ended December 31, 2003. Revenues were $96 million for the fourth quarter, a 5% increase compared to revenues of $91 million for the fourth quarter of 2002. Net income for the quarter was $4.0 million or $0.19 per diluted share as compared to net income of $3.0 million or $0.14 per diluted share for the prior year period.

For year ended December 31, 2003, revenues increased 11% to $355 million from $320 million for the prior year. Reported net income was $8.7 million or $0.41 per diluted sharefor the year ended December 31, 2003 as compared to $14.1 million or $0.67 per diluted share for 2002. As previously announced, the company recorded a pretax charge during the third quarter of 2003 of $8.7 million or $0.24 per diluted share related to additional bad debt reserves, restructuring costs and other miscellaneous expenses. In addition, during the fourth quarter of 2002, the company recorded a $1.7 million charge or $0.05 per diluted share related to the disposal of two operating locations.

Raj Rai, Option Care's chief executive officer commented, "We are pleased with our fourth quarter results. From the third quarter we realized sequential growth in revenues from both home infusion and specialty pharmacy services. We also realized costsavings as a result of our efforts from the restructuring announced in the third quarter. Additionally, during the fourth quarter, specialty pharmacy revenues increased with the start of the Synagis(R) season and our launch of Xolair(R). Finally, we are debt free with $4 million of cash on hand and, as a result, we spent $1.1 million in January on our stock buy-back program."

Rai continued, "We are concentrating on building our pipeline of new managed care and manufacturer relationships. In addition, during January we hired Rob Monahan as our Vice President of Acquisitions and completed two small transactions in markets we currently serve. Considering our investment in internal resources and our strong cash flow and access to capital, I expect to further increase our acquisition activities during the remainder of the year. We are excited about our growth opportunities and look forward to a successful 2004."

Rick Smith, Option Care's president and chief operating officer commented, "We have seen the beginning of the desired effects of the reorganization implemented during the third quarter. Specifically, we have seen an increase in focused revenue generating activity and implementation of efficient operating practices throughout the organization. In addition, overall cash flow continues to be very strong however, further improvements in cash collections remains a top priority. I am confident that our focused actions will continue our revenue growth, strengthen the operating structure of the company and drive earnings growth in 2004."

Commenting on the financial aspects of the quarter, Paul Mastrapa, chief financial officer commented, "Overall revenue growth on a same store basis for our company owned locations for only our infusiontherapy and specialty pharmacy services was 8% for the fourth quarter and 9% for the full year. Overall gross profit for the fourth quarter declined to 29.7% as compared to 30.7% for the prior year quarter due to a combination of the revenue mix between infusion and specialty pharmacy services, as well as the therapy mix within our specialty pharmacy services. In terms of revenue mix, infusion therapy comprised 36.6% of revenues in the fourth quarter as compared to 38.0% for the prior year fourth quarter. The infusion and related healthcare services gross profit was 43.5% as compared to 43.6% for the prior year fourth quarter. Specialty pharmacy services gross profit declined to 17.5% for the fourth quarter of this year as compared to 19.4% for the prior year period due to therapy mix and the increase in sales of Xolair(R) and Synagis(R) which have a lower gross margin than our composite gross margin."

Mastrapa continued, "During the fourth quarter, we realized a net gain of $0.8 million or $0.02 per diluted share related to the early termination of a franchise agreement as well as residual reorganization related expenses of $0.4 million or $0.01 per diluted share. Combined, our net gain was $0.4 million or $0.01 per diluted share. Finally, our balance sheet remains very strong with positive cash flow from operations of $4.8 million during the fourth quarter and $28 million for the year. I am pleased with our cash flow results considering the sequential increase in revenues from the third quarter of $13 million. Our strong cash flow is a reflection of our continued improvement in accounts receivable. Days sales outstanding were 61 days at the end of the fourth quarter, a decrease of 5 days from the previous quarter. Lastly, we ended the fourth quarter debt free with $4.0 million of cash on- hand."

2004 Guidance

The company affirms previously released earnings guidance. Earnings per diluted share are estimated to range between $0.73 to $0.77 for 2004.

Fourth Quarter ConferenceCall

The Company will be hosting a conference call today to review the financial results for the fourth quarter. Investors and other interested parties may access the call at 9:00 a.m. Central Time by dialing in at (800) 901-5231, participant passcode56641985.

The call will be broadcast live as well as replayed through the Internet. The webcast can be accessed through a link at http://www.optioncare.com/ . For those who cannot listen to the live broadcast, a replay will be available two hours after the call concludes at (888) 286-8010, passcode 32979107. The playback will be available until midnight on February 20, 2004.

The webcast is also being distributed over CCBN's Investor Distribution Network to both institutional and individual investors. Individual investors can listen to the call through CCBN's individual investor center at http://www.fulldisclosure.com/ or by visiting any of the investor sites in CCBN's Individual Investor Network. Institutional investors can access the call via CCBN's password-protected event management site, StreetEvents http://www.streetevents.com/.

About Option Care

Option Care provides various home infusion therapies and specialty pharmacy services to patients at home and other alternate sites such as infusion suites and physician's offices. The company's services and pharmaceuticals are provided nationally through its network of pharmacies.

Forward Looking Statements

This press release contains certain forward-looking statements within the meaning ofSection 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by the safe harbors created thereby. Forward looking statements can be identified by the use ofterms such as "anticipates," "expects," "believes" and other words having a similar meaning. Investors are cautioned that all forward-looking statements involve risks and uncertainty. Such forward-looking information involves important risks and uncertainties that could significantly affect anticipated results in the future and, accordingly, such results may differ from those expressed in any forward-looking statements made by us, or on our behalf. These risks and uncertainties include, but are not limited to, uncertainties affecting our businesses and our franchisees relating to acquisitions and divestitures (including continuing obligations with respect to completed transactions), sales and renewals of franchises, government and regulatory policies (including federal, state and local efforts to reform the delivery of and payment for healthcare services), general economic conditions (including economic conditions affecting the healthcare industry in particular), the pricing and availability of equipment and services, technological developments and changes in the competitive environment in which we operate. These statements are based upon assumptions and, although the Company believes that the assumptions underlying the forward-looking statements contained herein are reasonable, there can be no assurance that the forward-looking statements included in this press release will prove to be accurate.

Further Information on Option Care can be found at: http://www.optioncare.com/ .

OPTION CARE, INCORPORATED CONDENSED CONSOLIDATED STATEMENTS OF INCOME (in thousands, except per share data)

Three Months Ended Year Ended December 31, December 31, 2003 2002 2003 2002 Revenue: Specialty pharmacy services $57,304 $54,349 $208,557 $181,049 Infusion and related healthcare services 35,023 34,706 136,192 129,146 Other 3,379 2,336 10,691 10,301 Total revenue 95,706 91,391 355,440 320,496

Cost of revenue: Cost of goods sold 56,843 53,178 205,916 183,329 Cost of services provided 10,422 10,202 41,438 37,550 Total cost of revenue 67,265 63,380 247,354 220,879

Gross profit 28,441 28,011 108,086 99,617

Selling, general and administrative expenses 18,960 18,617 75,601 65,386 Provision for doubtful accounts 1,969 3,320 14,274 7,747 Depreciation and amortization 672 1,039 3,155 2,944 Total operating expenses 21,601 22,976 93,030 76,077

Operating income 6,840 5,035 15,056 23,540

Interest income (expense), net 21 (86) (261) (166) Other expense, net (243) (70) (350) (171)

Income before income taxes 6,618 4,879 14,445 23,203 Income tax provision 2,648 1,929 5,727 9,124

Net income $3,970 $2,950 $8,718 $14,079

Net income per share: Basic $0.19 $0.14 $0.42 $0.68 Diluted $0.19 $0.14 $0.41 $0.67

Shares used in computing net income per common share: Basic 21,031 20,747 20,888 20,656 Diluted 21,404 21,075 21,292 21,136

OPTION CARE, INCORPORATED CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands)

December 31, December 31, 2003 2002 Assets Current assets: Cash and cash equivalents $3,961 $488 Accounts receivable, net 62,190 74,694 Inventory 11,522 7,538 Other current assets 9,721 6,445 Total current assets 87,394 89,165

Equipment and other fixed assets, net 12,145 11,898 Goodwill, net 64,970 55,412 Other assets 2,025 2,375 Total assets $166,534 $158,850

Liabilities and stockholders' equity Current liabilities: Trade accounts payable $19,940 $14,559 Current portion of long-term debt 424 261 Other current liabilities 10,253 12,635 Total current liabilities 30,617 27,455

Long-term debt, excluding current portion 82 7,314 Other liabilities 6,815 5,480 Total liabilities 37,514 40,249

Total stockholders' equity 129,020 118,601

Total liabilities and stockholders' equity $166,534 $158,850

OPTION CARE, INCORPORATED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOW (in thousands)

Three Months Ended Year Ended December 31, December 31, 2003 2002 2003 2002

Cash flows from operating activities: Net income $3,970 $2,950 $8,718 $14,079

Non-cash expenses 2,605 5,358 20,272 13,618 Changes in assets and liabilities: Accounts receivable (8,174) (8,672) (1,820) (19,297) Other assets and liabilities 6,377 4,414 801 3,592

Net cash provided by operating activities 4,778 4,05027,971 11,992

Cash flows from investing activities: Payments for acquisitions (224) (596) (14,560) (20,938) Net purchases of equipment (1,007) (1,861) (4,656) (7,286) Other investing activities - 4 229 (63)

Net cash used in investing activities (1,231) (2,453) (18,987) (28,287)

Cash flows from financing activities: Net borrowing (repayments) on credit agreements (3,593) (1,354) (7,093) 7,093 Proceeds from issuance of stock 363 22 1,719 2,112 Other financing activities 77 (80) (137) (933)

Net cash provided by (used in) financing activities (3,153) (1,412) (5,511) 8,272

Net increase (decrease) in cash and cash equivalents 394 185 3,473 (8,023)

Cash and cash equivalents, beginning of period 3,567 303 488 8,511

Cash and cash equivalents, end of period $3,961 488 $3,961 $488

DATASOURCE: Option Care, Inc.

CONTACT: Paul Mastrapa, Chief Financial Officer, of Option Care,

+1-847-229-7773

Web site: http://www.optioncare.com/

<< Back


Option Care (MM) Historical Chart Option Care (MM) Intraday Chart  
Period


LSE and PLUS quotes are live. NYSE and AMEX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions :: Contact Us :: Request an Exchange :: Affiliate Scheme
Copyright1999-2008 ADVFN PLC. Copyright and limited reproduction :: Privacy Policy :: Investment Warning :: Advertise with us :: Data accreditations :: Investor Relations :: Press office :: Jobs
ADDITIONAL SERVICES AVAILABLE FROM ADVFN
Upgrade - Click here for more information on ADVFN premium services Money Words - ADVFN Financial Glossary Investor Training ADVFN Financial Bookshop Online Training Academy
38 site:2us 081006 21:11 Stock Message Boards ( 2001 | 2002 | 2003 | 2004 | 2005 | 2005 | 2007 )